HDC to develop breast cancer prognostic test
This article was originally published in Clinica
Executive Summary
Pattern recognition technology specialist Health Discovery Corporation (HDC) is set to team up with Smart Personalized Medicine (SPM) to develop a breast cancer test. The two firms will create the test using HDC’s support vector machine (SVM) technology and will collaborate with the MD Anderson Cancer Center in Houston, Texas, for the product’s development. This partnership will see HDC (Savannah, Georgia) receive a 15% equity stake in SPM, as well as a $5m initial investment from its new partner. HDC will also receive a royalty for each test sold of up to 7.5% based on net proceeds. No further financial details were disclosed. According to HDC, its SVM technology allows scientists to access information in micro-array datasets that more advanced bioinformatics techniques miss. SPM was formed by former Integra Life Sciences chairman Dr Richard Caruso.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals